RockerG, BourbeauJ, DownarJ: The new “opioid crisis”: Scientific bias, media attention, and potential harms for patients with refractory dyspnea. J Palliat Med, 2018; 21:120–122.
2.
VozorisNT, WangX, FischerHD, et al.: Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J, 2016; 48:683–693.
3.
VozorisNT, WangX, AustinPC, et al.: Adverse cardiac events associated with incident opioid drug use among older adults with COPD. Eur J Clin Pharmacol, 2017; 73:1287–1295.
4.
AhmadiZ, BernelidE, CurrowDC, EkstromM: Prescription of opioids for breathlessness in end-stage COPD: A national population-based study. Int J Chron Obstruct Pulmon Dis, 2016; 11:2651–2657.
5.
VandenbrouckeJP, PsatyBM: Benefits and risks of drug treatments: How to combine the best evidence on benefits with the best data about adverse effects. JAMA, 2008; 300:2417–2419.
